GET DAILY SIGNALSRegeneron Pharmaceuticals (REGN) Climbs +26% Over 30 Days After Strong Q3 Earnings
Key Takeaways
- Regeneron Pharmaceuticals (REGN) climbed roughly 26% over the past 30 days, from a closing price of $734.81 on October 1, 2026, to $927.89 on October 30, 2026, reaching a new 52-week high.
- The move was driven primarily by a third-quarter earnings beat reported on October 30: revenue of $5.12 billion (up 36% year over year) and non-GAAP EPS of $20.07 (up 70% year over year).
- Shares surged about 13.3% in a single session on October 30 on record quarterly sales for Dupixent, EYLEA HD, and Libtayo.
- Over the broader three-month period, the stock advanced roughly 22%, supported by double-digit revenue and earnings growth for a third consecutive quarter.
- Key catalysts include an expanded Sanofi collaboration and full recognition of Regeneron's share of Dupixent-related profits after Sanofi repaid its development balance.
- Investors can explore detailed Price Targets, Earnings, and Forecast data on additional pages for deeper context on REGN.
Understanding Regeneron Pharmaceuticals (REGN) and Its Market Position
Regeneron Pharmaceuticals, Inc., headquartered in Tarrytown, New York, is a global biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Its flagship products include Dupixent (dupilumab), an immunology blockbuster commercialized through its collaboration with Sanofi (SNY); EYLEA and EYLEA HD (aflibercept) for retinal diseases; and Libtayo (cemiplimab), an oncology immunotherapy. The company also markets products such as Praluent, Evkeeza, Lynozyfic, and Inmazeb.
Regeneron's competitive strengths include its VelocImmune antibody-generation technology, the Regeneron Genetics Center, and a broad late-stage pipeline spanning immunology, oncology, ophthalmology, genetic medicines, and cardiometabolic disease. From what I see, investors closely track the company for Dupixent's durable growth, the EYLEA HD product transition, and a pipeline of potential blockbusters. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
REGN Stock Price Performance: Last 30 Days vs. the Quarter
Over the last 30 days, REGN shares rose approximately 26%, moving from $734.81 at the October 1, 2026 close to $927.89 at the October 30, 2026 close. The advance was concentrated in a single dramatic session, when the stock jumped roughly 13.3% on October 30 following third-quarter results, pushing the shares to a new 52-week high.
Across the broader quarter, the trend was similarly positive. From a close of $762.63 on July 31, 2026, the stock climbed to $927.89 by October 30, a gain of about 22%. The path was not linear: shares pulled back through late September and early October to an intraday low near $722 before recovering sharply into earnings. The overall pattern reflects sustained fundamental momentum punctuated by a major earnings-driven repricing. One thing that stands out is how the recovery aligned tightly with the earnings release.
What Drove REGN Stock Price in the Last 30 Days
The primary catalyst was the October 30 third-quarter earnings report. Regeneron posted total revenue of $5.12 billion, up 36% year over year and above consensus estimates near $4.5 billion, while non-GAAP diluted EPS of $20.07 rose 70% year over year and beat analyst expectations of roughly $16 per share. Net income reached $1.95 billion.
Growth was powered by record quarterly sales across the company's core franchises. Dupixent global sales, recorded by Sanofi, rose 35% to approximately $6.54 billion, with U.S. sales exceeding $5 billion for the first time. EYLEA HD U.S. sales climbed 62% to $699 million, while Libtayo global sales rose 51% to a record $550 million. The company also began recognizing its full share of collaboration profits after Sanofi completed repayment of its development balance.
Additional drivers included the October expansion of the Sanofi antibody alliance, carrying a $1.0 billion upfront payment and up to $7.0 billion in potential milestones, plus an agreement with the Biomedical Advanced Research and Development Authority (BARDA) to supply Inmazeb for Ebola preparedness. Regeneron also raised its 2026 adjusted gross margin outlook to about 86%. Analyst activity was mixed, with Sanofi-linked coverage reflecting a Hold from RBC Capital ($810 target) and a Buy reiteration from Canaccord Genuity ahead of the report.
What Drove REGN Stock Performance Over the Last Quarter
The roughly 22% quarterly gain reflected a third consecutive quarter of double-digit top- and bottom-line growth and growing confidence in the company's commercial execution. The October expansion of the Sanofi collaboration and the full recognition of Dupixent-related profits removed a long-standing drag on reported revenue, while EYLEA HD's growth continued to offset erosion in legacy EYLEA sales from biosimilar competition.
Pipeline momentum also supported sentiment. Regeneron highlighted an expected U.S. Food and Drug Administration decision on cemdisiran for generalized myasthenia gravis, presented long-term Phase 3 Libtayo data showing a 37% reduction in the risk of death in cutaneous squamous cell carcinoma, and reported early CIDEB siRNA data in metabolic liver disease. Share repurchases, totaling $2.3 billion in the first nine months of 2026, provided additional support to per-share metrics. I’m watching this closely as the pipeline data rolls in.
REGN Stock Forecast Drivers: What Investors Should Watch Next
Several near-term catalysts could shape REGN shares. Investors are monitoring an expected FDA decision on cemdisiran for generalized myasthenia gravis in November 2026, potential approval of the EYLEA HD prefilled syringe, and pivotal combination data in paroxysmal nocturnal hemoglobinuria expected by year-end. First-in-human CIDEB siRNA data for metabolic liver disease is also expected to be presented at an upcoming liver meeting.
Key risks include continued pricing and biosimilar pressure on the legacy EYLEA franchise, the durability of Dupixent growth, and rising expenses. Regeneron guided 2027 R&D spending up by a mid-teens percentage and flagged an expected 100–200 basis point increase in its effective tax rate. Following the earnings surge, the stock also trades above some published analyst price targets, underscoring the importance of execution and pipeline delivery in the months ahead.
Exploring Tickeron’s Trending AI Robots for Market Insights
In my own analysis, I often review Tickeron’s Trending AI Robots to get a sense of which automated strategies are gaining traction across thousands of tickers. The section highlights top-performing bots with different approaches and timeframes, updated based on recent results. It offers a practical way to compare data-driven methods without building everything from scratch. I find it useful for spotting patterns in volatile sectors like biotech.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
REGN in upward trend: 10-day moving average broke above 50-day moving average on October 26, 2026
The 10-day moving average for REGN crossed bullishly above the 50-day moving average on October 26, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 14 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 12, 2026. You may want to consider a long position or call options on REGN as a result. In 58 of 92 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 63%.
The Moving Average Convergence Divergence (MACD) for REGN just turned positive on October 14, 2026. Looking at past instances where REGN's MACD turned positive, the stock continued to rise in 32 of 50 cases over the following month. The odds of a continued upward trend are 64%.
REGN moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +14.09% 3-day Advance, the price is estimated to grow further. Considering data from situations where REGN advanced for three days, in 202 of 314 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.
Bearish Trend Analysis
The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 12 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where REGN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 56%.
REGN broke above its upper Bollinger Band on October 30, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for REGN entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 5 (best 1 - 100 worst), indicating outstanding price growth. REGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 59 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 65 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock slightly better than average.
The Tickeron Valuation Rating of 89 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.013) is normal, around the industry mean (3.162). P/E Ratio (22.161) is within average values for comparable stocks, (-1.064). Projected Growth (PEG Ratio) (1.238) is also within normal values, averaging (9.059). Dividend Yield (0.004) settles around the average of (131.622) among similar stocks. P/S Ratio (5.339) is also within normal values, averaging (439.647).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of medicines for the treatment of serious medical conditions
Industry Biotechnology
Advertisement